[Form 4] Perfect Moment Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Cingulate Inc. (CING) filed a Form 4 reporting two stock-option grants to Raul R. Silva, EVP & Chief Scientific Officer.

• Grant 1: 1,000 options to buy common stock at an exercise price of $4.30 per share. Grant and first exercisable date: 03/31/2025; expiration: 03/31/2035.
• Grant 2: 1,000 options at an exercise price of $4.07 per share. Grant and first exercisable date: 06/30/2025; expiration: 06/30/2035.

Both grants were made pursuant to Dr. Silva’s employment agreement and are held directly. No open-market purchases or sales of common stock were reported, and Table I shows no changes in non-derivative holdings. Post-transaction, Dr. Silva beneficially owns 1,000 derivative securities in each grant line, representing incentive alignment but a modest absolute share count.

Insights

Securities Analyst

TL;DR Small option grants to an officer; routine incentive alignment, limited market impact.

The reported grants total 2,000 options with 10-year lives and strike prices in the low-$4 range, roughly aligning with typical at-the-money compensation awards for emerging biopharma executives. Because no common shares were bought or sold for cash, there is no immediate liquidity signal. The size is immaterial relative to most public floats, so market impact should be negligible. Nonetheless, the issuance extends retention incentives and ties compensation to long-term shareholder value.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gottschalk Max

(Last) (First) (Middle)

244 5TH AVENUE

SUITE 1219

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perfect Moment Ltd. [ PMNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		P		1,692,694(1)	A	$0.3	2,024,447	I	By Joachim Gottschalk & Associates Ltd.(2)
Common Stock								47,020	D
Common Stock								316,600	I	By Reporting Person's Spouse(3)
Common Stock								3,479,491	I	By Fermain Limited(4)
Series AA Preferred Stock								344,797	I	By Joachim Gottschalk & Associates Ltd.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Issuer entered into a Securities Purchase Agreement (the "Agreement") with Joachim Gottschalk & Associates ("JGA"). Further to the Agreement, JGA, converted all principal and unpaid interest owing further to a promissory note evidencing a $500,000 loan previously made by JGA to the Issuer into 1,692,694 shares of common stock at a per share conversion rate of $0.30. See also footnote 2.

2. The Gottschalk Family Trust is the 100% owner of Joachim Gottschalk & Associates Ltd. and Credit Suisse Trust Limited is the Trustee of the Gottschalk Family Trust. Credit Suisse Trust Limited takes direction from the Reporting Person's Spouse, as a beneficiary of the Gottschalk Family Trust. The Reporting Person disclaims beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is a beneficial owner of the securities reported in this filing for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

3. Shares owned by Reporting Person's spouse Jane Gottschalk. Reporting Person and his spouse each share voting and dispositive control over the shares of common stock beneficially owned by the other.

4. Fermain Limited ("Fermain") is controlled by Reporting Person and his spouse, Jane Gottschalk, each of whom shares voting and dispositive control over Fermain's shares with no single person controlling investment or voting decisions with respect to such shares. Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. Inclusion of shares owned by Fermain shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended..

Remarks:

	/s/ Max Gottschalk	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CING insider Raul R. Silva report on the Form 4?

He received two stock-option grants totaling 2,000 options with strikes of $4.30 and $4.07 per share.

Were any Cingulate Inc. common shares bought or sold by the insider?

No. The filing shows no acquisitions or disposals of non-derivative common stock.

What are the exercise and expiration dates of the options?

Grant 1: exercisable 03/31/2025, expires 03/31/2035. Grant 2: exercisable 06/30/2025, expires 06/30/2035.

How many derivative securities does Dr. Silva own after these grants?

The filing lists 1,000 options under each grant line, held directly.

Does the filing indicate a 10b5-1 trading plan?

The form includes the new Rule 10b5-1(c) checkbox, but it is not marked as selected.